Vertex Pharmaceuticals Interest Income decreased by 3.0% to $121.90M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 4.9%, from $128.20M to $121.90M. Over 4 years (FY 2021 to FY 2025), Interest Income shows an upward trend with a 216.4% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Higher interest income suggests a strong cash position or a favorable interest rate environment for the company's investments.
Interest income is the revenue earned from cash deposits, marketable securities, and other interest-bearing investments....
Varies based on cash management strategies; companies with large cash piles will report higher interest income than those with high debt.
is_interest_income| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.13M | $1.12M | $1.19M | $1.60M | $10.80M | $46.20M | $86.00M | $122.60M | $144.70M | $167.90M | $179.50M | $181.20M | $156.50M | $132.20M | $128.20M | $120.90M | $122.40M | $125.70M | $121.90M |
| QoQ Change | — | -1.5% | +6.3% | +34.9% | +575.0% | +327.8% | +86.1% | +42.6% | +18.0% | +16.0% | +6.9% | +0.9% | -13.6% | -15.5% | -3.0% | -5.7% | +1.2% | +2.7% | -3.0% |
| YoY Change | — | — | — | — | +853.2% | >999% | >999% | >999% | >999% | +263.4% | +108.7% | +47.8% | +8.2% | -21.3% | -28.6% | -33.3% | -21.8% | -4.9% | -4.9% |